Scientific exchange · Dr. William Abbott

10 May 2026 · Virtual · Dr. William Abbott, Universitätsklinikum Heidelberg · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0077—

Capture insight from this engagement

Location: Universitätsklinikum Heidelberg
Therapeutic area: Oncology
Country: Germany
Stakeholder tier: Tier 3
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data
Chemotherapy-free first line

Scientific content used

PD-L1 testing pathway infographic

Questions raised

How should grade 2 infusion reactions be managed without steroids?
Is there subgroup data for patients with untreated brain metastases?

Notes

Scientific exchange with radiation oncologist at Universitätsklinikum Heidelberg. Discussed brain-metastasis subgroup data, chemotherapy-free first line.

Insights captured (1)

Capture insight

INS-0065Medium
Brain-metastasis subgroup data
Brain-metastasis subgroup data: interest in collaboration reported by radiation oncologist (DE).
Deduplicated

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 4
Depth of exchange: 4
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0077

Audit history (0)

All create, update and approval events for this record

No audit events in sample data